Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8IC5H)

Drug Name
TRICIRIBINE Drug Info
Synonyms
NSC154020; Akt Inhibitor V, Triciribine; MLS002702033; Akt/PKB Signaling Inhibitor-2; NSC-154020; TCN; Akt inhibitor V; AC1Q7CGY; AC1L6DVE; tricyclic nucleoside (TCN); SCHEMBL61269; GTPL5920; CHEMBL1892348; CHEBI:91697; HMS3268N05; HMS3654C06; HMS3229A09; HSCI1_000386; CCG-206732; 5-methyl-1-pentofuranosyl-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine; SMR001565606; SC-89664; NCI60_001091; Akt/protein kinase B signaling inhibitor-2; BRD-A42649439-001-01-0; BRD-A42649439-001-02-8; 1,5,6,8-Pentaazaacennaphthylen-3-amine, 1,5-dih
Cross-matching ID
PubChem CID
65399
ChEBI ID
CHEMBL331237
CAS Number
CAS 35943-35-2
TTD Drug ID
D04GSV
INTEDE Drug ID
DR1821

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
FoxO signaling pathway 2.03 1.05e-2 118/131 (90.08%) CCNG2;TNFSF10;IGF1R;...
Mitophagy 1.87 2.62e-2 56/68 (82.35%) SQSTM1;FOXO3;KRAS;...
Autophagy 1.83 2.79e-2 113/169 (66.86%) SQSTM1;IGF1R;DDIT4;...
Adipocytokine signaling pathway 1.80 2.62e-2 64/69 (92.75%) NFKBIA;IRS2;TNFRSF1A;...
MAPK signaling pathway 1.79 2.51e-2 272/294 (92.52%) MYC;IL1R1;DUSP4;...
Wnt signaling pathway 1.78 2.09e-2 124/166 (74.7%) MYC;SFRP1;PLCB1;...
C-type lectin receptor signaling pathway 1.78 1.79e-2 93/104 (89.42%) NFKBIA;CALML5;IL6;...
Chronic myeloid leukemia 1.76 2.09e-2 72/76 (94.74%) MYC;NFKBIA;GAB2;...
ErbB signaling pathway 1.76 1.86e-2 79/85 (92.94%) MYC;AREG;CDKN1B;...
Notch signaling pathway 1.75 2.20e-2 49/59 (83.05%) PSEN1;NCOR2;HEY1;...
MicroRNAs in cancer 1.74 2.47e-2 146/310 (47.1%) MYC;MET;SOX4;...
Fluid shear stress and atherosclerosis 1.74 2.35e-2 123/139 (88.49%) IL1R1;ARHGEF2;CALML5;...
Osteoclast differentiation 1.72 2.74e-2 117/127 (92.13%) IL1R1;NFKBIA;JUND;...
TGF-beta signaling pathway 1.67 4.71e-2 81/94 (86.17%) MYC;TGIF1;ACVR1B;...
Chagas disease 1.65 4.74e-2 93/102 (91.18%) NFKBIA;PLCB1;IL6;...
Glycine, serine and threonine metabolism -1.64 2.39e-2 31/40 (77.5%) GATM;GAMT;SRR;...
Retinol metabolism -1.66 2.13e-2 41/68 (60.29%) RDH16;LRAT;HSD17B6;...
Allograft rejection -1.66 2.01e-2 32/38 (84.21%) GZMB;HLA-C;HLA-A;...
RNA polymerase -1.67 2.08e-2 23/31 (74.19%) POLR2K;POLR2G;POLR2E;...
Progesterone-mediated oocyte maturation -1.67 2.16e-2 75/100 (75%) HSP90AB1;CCNA1;IGF1;...
Fructose and mannose metabolism -1.69 1.84e-2 30/33 (90.91%) FPGT;PFKFB2;SORD;...
Type I diabetes mellitus -1.71 1.52e-2 38/43 (88.37%) GZMB;HLA-C;HLA-A;...
Parkinson disease -1.71 1.59e-2 176/249 (70.68%) COX6B1;PSMC5;COX7C;...
Citrate cycle (TCA cycle) -1.71 1.66e-2 30/30 (100%) PDHA1;SUCLG2;SUCLG1;...
Diabetic cardiomyopathy -1.72 1.65e-2 162/203 (79.8%) COX7A2;INSR;NDUFB5;...
Steroid biosynthesis -1.72 1.74e-2 19/20 (95%) CYP27B1;LBR;TM7SF2;...
Systemic lupus erythematosus -1.76 1.18e-2 45/135 (33.33%) SNRPD1;HLA-DPA1;C2;...
Autoimmune thyroid disease -1.79 1.15e-2 46/53 (86.79%) IFNA1;CD28;IL10;...
Fanconi anemia pathway -1.81 9.38e-3 36/54 (66.67%) FANCE;USP1;TELO2;...
Pentose phosphate pathway -1.83 7.03e-3 25/30 (83.33%) TKT;G6PD;ALDOB;...
RNA degradation -1.85 6.25e-3 53/79 (67.09%) LSM7;PABPC3;EXOSC4;...
Glyoxylate and dicarboxylate metabolism -1.90 2.01e-3 23/30 (76.67%) CS;ACO2;HAO1;...
Glycolysis / Gluconeogenesis -1.94 2.16e-3 56/67 (83.58%) ADH1B;ALDH1B1;PDHA1;...
Homologous recombination -1.97 7.82e-4 35/41 (85.37%) BRCC3;BLM;RAD51;...
Base excision repair -1.99 0.00e+0 29/33 (87.88%) POLE;NEIL3;HMGB1;...
Ribosome -2.00 0.00e+0 113/158 (71.52%) RPS18;RPS14;RPS8;...
Drug metabolism -2.01 0.00e+0 78/151 (51.66%) GSTM5;CES1;CYP2E1;...
Mismatch repair -2.03 0.00e+0 22/23 (95.65%) PCNA;RFC4;MLH1;...
Spliceosome -2.04 0.00e+0 101/150 (67.33%) LSM7;SNRPD1;DDX42;...
Cell cycle -2.04 0.00e+0 110/124 (88.71%) RB1;HDAC1;DBF4;...
Nucleotide excision repair -2.06 0.00e+0 40/47 (85.11%) RFC4;GTF2H4;DDB1;...
Oxidative phosphorylation -2.09 0.00e+0 93/133 (69.92%) COX11;COX7A2;PPA2;...
Asthma -2.09 0.00e+0 25/31 (80.65%) HLA-DPA1;FCER1G;HLA-DOB;...
Protein export -2.22 0.00e+0 17/23 (73.91%) SRP9;SRPRA;OXA1L;...
DNA replication -2.68 0.00e+0 34/36 (94.44%) POLE;DNA2;MCM6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H